These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 2564593)

  • 1. Human monoclonal antibody to ganglioside GM2 for melanoma treatment.
    Irie RF; Matsuki T; Morton DL
    Lancet; 1989 Apr; 1(8641):786-7. PubMed ID: 2564593
    [No Abstract]   [Full Text] [Related]  

  • 2. Human IgM antibody therapy for HIV-1 infection.
    Okada N; Okada H
    Microbiol Immunol; 1999; 43(8):729-36. PubMed ID: 10524789
    [No Abstract]   [Full Text] [Related]  

  • 3. Therapeutic Strategies for Human IgM Antibodies Directed at Tumor-Associated Ganglioside Antigens: Discoveries Made During the Morton Era and Future Directions.
    Jones PC; Irie RF
    Crit Rev Oncog; 2016; 21(1-2):75-81. PubMed ID: 27481004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human monoclonal antibody with dual GM2/GD2 specificity derived from an immunized melanoma patient.
    Yamaguchi H; Furukawa K; Fortunato SR; Livingston PO; Lloyd KO; Oettgen HF; Old LJ
    Proc Natl Acad Sci U S A; 1990 May; 87(9):3333-7. PubMed ID: 2159145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.
    Livingston PO; Natoli EJ; Calves MJ; Stockert E; Oettgen HF; Old LJ
    Proc Natl Acad Sci U S A; 1987 May; 84(9):2911-5. PubMed ID: 3472242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside.
    Livingston PO; Ritter G; Srivastava P; Padavan M; Calves MJ; Oettgen HF; Old LJ
    Cancer Res; 1989 Dec; 49(24 Pt 1):7045-50. PubMed ID: 2582446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyotrophic lateral sclerosis with IgM antibody against gangliosides GM2 and GD2.
    Mizutani K; Oka N; Kusunoki S; Kaji R; Kanda M; Akiguchi I; Shibasaki H
    Intern Med; 2003 Mar; 42(3):277-80. PubMed ID: 12705795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal antibody directed to a Hanganutziu-Deicher active ganglioside, GM2 (NeuGc).
    Sanai Y; Yamasaki M; Nagai Y
    Biochim Biophys Acta; 1988 Feb; 958(3):368-74. PubMed ID: 2449247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the binding epitope of the monoclonal antibody DMAb-1 to ganglioside GM2.
    Karlsson G; Månsson JE; Wikstrand C; Bigner D; Svennerholm L
    Biochim Biophys Acta; 1990 Apr; 1043(3):267-72. PubMed ID: 1691018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine.
    Kitamura K; Livingston PO; Fortunato SR; Stockert E; Helling F; Ritter G; Oettgen HF; Old LJ
    Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2805-9. PubMed ID: 7708728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Five new epitope-defined monoclonal antibodies reactive with GM2 and human glioma and medulloblastoma cell lines.
    Vrionis FD; Wikstrand CJ; Fredman P; Månsson JE; Svennerholm L; Bigner DD
    Cancer Res; 1989 Dec; 49(23):6645-51. PubMed ID: 2479468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunohistological study of the mechanism of cytotoxic effect against cutaneous metastatic malignant melanoma by intralesional injection with anti-monosialoganglioside mouse monoclonal antibody (MAb 202)].
    Ota T; Imamura T; Hamanaka S; Nishioka K; Tai T; Kawashima I; Irie RF; Asagami C
    Nihon Hifuka Gakkai Zasshi; 1988 Aug; 98(9):913-22. PubMed ID: 3244169
    [No Abstract]   [Full Text] [Related]  

  • 13. Chimeric anti-ganglioside GM2 antibody with antitumor activity.
    Nakamura K; Koike M; Shitara K; Kuwana Y; Kiuragi K; Igarashi S; Hasegawa M; Hanai N
    Cancer Res; 1994 Mar; 54(6):1511-6. PubMed ID: 8137257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-GM2, -GD1a and -GD1b positive purely isolated facial diplegia.
    Vachalová I; Golden V; Heckmann JG
    Clin Neurol Neurosurg; 2014 Jul; 122():131-2. PubMed ID: 24813327
    [No Abstract]   [Full Text] [Related]  

  • 15. Ganglioside vaccines with emphasis on GM2.
    Livingston P
    Semin Oncol; 1998 Dec; 25(6):636-45. PubMed ID: 9865678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe sensory ataxia and demyelinating polyneuropathy with IgM anti-GM2 and GalNAc-GD1A antibodies.
    Lopate G; Choksi R; Pestronk A
    Muscle Nerve; 2002 Jun; 25(6):828-36. PubMed ID: 12115971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a proapoptotic antiganglioside GM2 monoclonal antibody and evaluation of its therapeutic effect on melanoma and small cell lung carcinoma xenografts.
    Retter MW; Johnson JC; Peckham DW; Bannink JE; Bangur CS; Dresser K; Cai F; Foy TM; Fanger NA; Fanger GR; Woda B; Rock KL
    Cancer Res; 2005 Jul; 65(14):6425-34. PubMed ID: 16024647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Approaches to augmenting the immunogenicity of the ganglioside GM2 in mice: purified GM2 is superior to whole cells.
    Livingston PO; Calves MJ; Natoli EJ
    J Immunol; 1987 Mar; 138(5):1524-9. PubMed ID: 3805726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside.
    Livingston PO; Wong GY; Adluri S; Tao Y; Padavan M; Parente R; Hanlon C; Calves MJ; Helling F; Ritter G
    J Clin Oncol; 1994 May; 12(5):1036-44. PubMed ID: 8164027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ganglioside GM2 as a human tumor antigen (OFA-I-1).
    Tai T; Paulson JC; Cahan LD; Irie RF
    Proc Natl Acad Sci U S A; 1983 Sep; 80(17):5392-6. PubMed ID: 6193515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.